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The most common type of cancer in the United States is non-melanoma skin 
cancer (NMSC), with an estimated two million new cases diagnosed each year.  
Numerous malignancies including NMSC, colon, breast, and prostate cancer 
overexpress cyclooxygenase-2 (COX-2).  COX-2 catalyzes the synthesis of 
prostaglandins including prostaglandin E2 (PGE2) which activates E-type prostaglandin 
(EP) receptors and promotes tumor development when overexpressed.  
Pharmacological inhibition or genetic deletion of COX-2 significantly decreases skin 
carcinogenesis mediated by the two-stage chemical carcinogenesis model using 7, 12-
dimethylbenz[a]anthracene (DMBA) and 12-O-tetradecanoylphorbol-13-acetate (TPA) 
or by UVB-light.  Apigenin is a non-mutagenic bioflavonoid present in various foods.  
Previous work in our lab has shown that apigenin blocks TPA- and UV-light induced 
COX-2 expression in vitro and apigenin also inhibits skin carcinogenesis; however, the 
mechanism by which apigenin blocks tumor formation is unclear.  These observations 
suggest that apigenin prevents chemically-induced tumor formation through the 
inhibition of the COX-2/PGE2 pathway.  In specific aim 1, our goal was to determine the 
acute effect of apigenin on TPA-induced COX-2 expression, PGE2 production, and EP 
receptor expression in vivo to gain a better understanding of the molecular mechanisms 
that may be responsible for its antitumor activity.  Female SKH-1 hairless mice were 
pretreated with apigenin or vehicle one hour before exposure to TPA.  Animals were 
euthanized 8 hours later and the epidermis isolated, pooled, and analyzed for COX-2 
expression, PGE2 production, and EP receptor expression.  Apigenin significantly 
inhibited COX-2 expression, PGE2 production, and EP1 receptor expression in the 
epidermis.  In specific aim 2, our goal was to determine if apigenin-mediated blockade 
of chemically-induced skin Tumorigenesis occurs as a result of the inhibition of COX-2 
expression, PGE2 production, and EP receptor expression.  Skin carcinogenesis was 
induced in animals using the two-stage chemical carcinogenesis model.  Female SKH-1 
mice were exposed to a single topical dose of DMBA (tumor initiating agent) followed by 
biweekly applications of TPA (tumor promoting agent) for 25 weeks.  Animals were 
treated one hour prior to TPA exposure with apigenin or vehicle.  At the end of the 
study, the number of tumors and the size of each tumor were determined.  Tumors and 
surrounding epidermal tissue were then harvested, classified, and subjected to 
immunohistochemical analysis.  Apigenin caused a dose-dependent decrease in tumor 
multiplicity and incidence in animals exposed to DMBA/TPA.  Apigenin significantly 
inhibited the chemically-mediated increase in COX-2 expression, PGE2 production, and 
EP receptor expression in skin surrounding the tumors whereas all tumors 
overexpressed COX-2.  In addition, apigenin increased terminal differentiation and 
decreased proliferation in the surrounding epidermis of tumor bearing animals.  
Collectively, our findings demonstrate that apigenin suppresses chemically-induced 
tumor formation and also inhibits COX-2 expression, PGE2 production, and EP receptor 
expression in the surrounding epidermis.  Inhibition of the COX-2/PGE2 pathway by 
apigenin may be responsible for its antitumor activity thus supporting the development 
of apigenin or apigenin-derivatives as chemopreventive agents for NMSC. 
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Chapter 1 
Introduction 
1.1 Epidemiology of skin cancer 
Skin cancer is a major public health concern throughout the world and represents 
more than half of all cancers diagnosed in the United States.  The most common type of 
skin cancer is non-melanoma skin cancer (NMSC) with an estimated two million new 
cases diagnosed each year (Rogers, et al., 2010; Siegel, et al., 2011).  One out of every 
five Americans will develop some form of skin cancer throughout their lifetime 
(Robinson, 2005).  Data analysis from a research survey conducted by Medicare 
revealed that between the years of 1992 and 2006 procedures and treatments 
associated with NMSC have increased over 77% and are among the most costly of all 
cancers (Stern, 2010; Housman, et al., 2003).  In a study conducted in 2004, total direct 
costs of NMSC in the United States were approximately $1.5 billion (Bickers, et al., 
2006).  Thus, identification of molecular mechanisms of tumor formation and 
development of novel chemotherapeutic agents is a primary focus in the battle against 
skin cancer.  
 
1.2 The skin 
The skin is the largest organ of the human body and serves as the first line of 
defense against a wide array of factors including physical, microbial, and chemical 
assaults (Jablonski and Chaplin, 2002; Jensen and Proksch, 2009).  Additionally, the 
skin regulates body temperature, provides insulation, produces energy, and synthesizes 
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vitamin D (Jablonski and Chaplin, 2002; Jensen and Proksch, 2009).  The skin is 
composed of three distinct layers: the epidermis, dermis, and hypodermis/subcutaneous 
layer (Figure 1).    
The epidermis is the most superficial layer and is primarily composed of 
keratinocytes but also houses melanocytes, Langerhans cells, and Merkel cells.  In 
humans, the epidermis can be further subdivided into stratified layers each 
corresponding to different stages of differentiation (Wysocki, 1999; Jablonski and 
Chaplin, 2002; Jensen and Proksch, 2009).  These layers include the stratum basale, 
stratum spinosum, stratum granulosum, stratum lucidum, and the stratum corneum 
(Figure 2).  The stratum basale or the basal layer is the innermost layer and is primarily 
composed of proliferating keratinocytes and is the site where mitosis takes place 
(Eckert and Rorke, 1989). Within the basal layer, terminal differentiation takes place as 
keratinocytes become anucleated (corneocytes) and migrate into the next layer, the 
stratum spinosum.  In the stratum spinosum cells synthesize cytokeratins that interact 
with desmosomes to collaborate and provide structural support.  The next layer is the 
stratum granulosum where squamous cells reside and appear granular due to small 
basophilic granules present within the cytoplasm.  The stratum lucidum is a clear 
translucent layer only appearing in the palms and soles in humans.  The stratum 
corneum is the outer most layer and serves as a physical barrier against chemical and 
infectious agents and also prevents dehydration.  In addition, as the dead cells slough 
off, they are continually replaced as cells terminally differentiate from the basal layer 
(Eckert and Rorke, 1989;Wysocki, 1999; Jablonski and Chaplin, 2002; Jensen and 
Proksch, 2009).  
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Directly below the epidermis lies the dermis, which provides strength and 
elasticity to the skin.  The dermis is composed of collagen, elastin, and proteoglycans 
and consists of various cell types including fibroblasts, macrophages, and adipocytes 
(Jensen and Proksch, 2009).  The dermis is connected to the epidermis through the 
basement membrane.  In addition, the dermis is vascularized which provides 
nourishment and waste removal for both the dermal and epidermal layer.  The bottom 
most layer is the hypodermis.  This layer is made up of subcutaneous fat and 
connective tissue and is responsible for binding the dermis to tissue/muscle (Wysocki, 
1999) 
1.3 Skin cancer 
There are two major categories of skin cancer: melanoma and non-melanoma 
skin cancer.  Melanoma accounts for a small percentage of skin cancer cases in the 
United States; however, the majority of deaths related to skin cancer are due to 
melanoma.  There are various forms of non-melanoma skin cancer with the two major 
types being basal cell carcinoma (BCC) and squamous cell carcinoma (SCC).  BCC is 
the most common form of NMSC and accounts for approximately 80% of all NMSC 
cases (Rogers, et al., 2010; Siegel, et al., 2011).  BCC develops within the basal layer 
of the epidermis and carries the potential for local destruction of tissue.  BCCs 
characteristically occur on sun-exposed areas of the skin, develop at a slow rate, rarely 
metastasize, and generally appear as a shiny, pearly-white nodule (McGuire, et al., 
2009).  On the other hand, SCCs are invasive tumors that have the potential to 
metastasize.  SCCs develop from squamous cells within the epidermis of the skin and 
appear as scaly or ulcerated lesions with raised edges and are asymmetric in shape 
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(Stulberg, et al., 2004; McGuire, et al., 2009).  SCCs account for approximately 20% of 
NMSC cases (Rogers, et al., 2010; Siegel, et al., 2011).  
 
1.4 Skin carcinogenesis 
 
Skin tumor development is a multistage molecular process that occurs as a result 
of various cellular, molecular, and biochemical changes.  There are a wide variety of 
agents that cause skin cancer including: industrial and environmental chemicals; 
viruses; and ultraviolet radiation (UV).  It is generally accepted that UV radiation is the 
major cause of skin cancer in humans (Afaq, et al., 2005).  Skin tumors develop as a 
consequence of acquiring mutations in genes that regulate cell proliferation, terminal 
differentiation, and apoptosis.  These genetic alterations ultimately enhance tumor cell 
growth and survival (Fischer, et al., 1989; Sarasin, 1999).  Various animal models are 
available to evaluate the molecular and cellular events that promote or prevent cancer.  
The most commonly used is the two-stage chemical carcinogenesis animal model 
developed in the late 1940s.   
The chemical carcinogenesis model involves three distinct stages; initiation, 
promotion, and progression (Figure 3) (Yuspa, et al., 1976).  Tumor initiation is an 
irreversible step achieved by a single cutaneous exposure to an agent that causes 
genetic mutations in genes encoding proto-oncogenes (i.e. H-ras) or tumor suppressor 
proteins (i.e. p53) (Barrett, 1993).  There are several tumor initiating agents (Table 1) 
with the most frequently used being 7, 12 - dimethylbenz[a]anthracene (DMBA).  DMBA 
is a polycyclic aromatic hydrocarbon that is metabolized by the cytochrome P450 
(CYP1B1) enzyme to its active form (DiGiovanni, 1992).  Once activated, DMBA 
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initiates an adenine (A) to thymine (T) transversion mutation in codon 61 of the H-ras 
gene.  This irreversible mutation can lead to cellular progression to a precancerous 
lesion following exposure to a tumor promoter (DiGiovanni, 1992; Hennings, et al., 
1993).  
Tumor promotion is a reversible process that involves inducing cellular 
proliferation and altering signal transduction in initiated cells, ultimately leading to the 
formation of pre-malignant and malignant lesions.  These lesions are achieved by 
repeated applications of a nonmutagenic pro-inflammatory agent (Yuspa, et al., 1976;  
Goel, et al., 2007).  The most commonly used experimental tumor promoting agent is 
the phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA).  Other tumor promoting 
agents include phenol, anthralin, and benzoyl peroxide (Table 1) (Yuspa, et al., 1976).  
TPA is a potent pro-inflammatory agent derived from the croton plant that activates the 
protein kinase C (PKC) signal transduction pathway and increases reactive oxygen 
species (ROS) production in keratinocytes (reviewed in Rundhaug and Fischer, 2010).  
TPA is also known to induce epidermal hyperplasia and edema, increase keratinocyte 
proliferation, and induce epidermal ornithine decarboxylase which is necessary for 
polyamine biosynthesis (Verma and Boutwell, 1980; Byus and Weiner, 1982; Slaga, 
1983; O'Brien, et al., 1997; Vargo, et al., 2006; Hara, et al., 2010 ).  As a result, 
promoting agents induce clonal expansion of the initiated cells and formation of a 
premalignant papilloma; however, only a small percentage of papillomas that develop 
will progress to a malignant tumor.   
The final step in skin cancer formation is tumor progression.  Tumor progression 
is characterized by enhanced cellular division and the accumulation of additional 
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genetic changes in the affected cells.  It is during this stage that a benign papilloma is 
converted to a malignant carcinoma with the ability to metastasize (Yuspa, et al., 1976; 
DiGiovanni, 1992).  
An alternative model for analyzing skin carcinogenesis in animals is the UV light-
induced photocarcinogenesis protocol.  UV radiation can be subdivided into three 
different spectrums corresponding to their wavelength; UVA (400 – 315 nm), UVB (315 
– 280), and UVC (280 – 100 nm).  Of the three, UVB is primarily responsible for skin 
cancer formation.  UV light is a complete carcinogen because it causes both tumor 
initiation and promotion.  One potential downfall is that the different stages of tumor 
development cannot be studied individually as in the two-stage chemical carcinogenesis 
protocol.  Acute cutaneous exposure to UV-light can trigger an inflammatory response 
and lead to erythema (sunburn).  Chronic exposure to UV, more specifically UVB, 
induces DNA damage through the formation of cyclobutyl pyrimidine dimers and 
pyrimidine (6-4) pyrimidinone photoproducts.  These types of DNA mutations occur 
commonly in genes encoding tumor suppressor proteins such as p53 and ultimately 
lead to tumor development (Sarasin, 1999; Afaq, et al., 2005).   
 
1.5 The cyclooxygenase inflammatory cascade 
A common characteristic of both chemically- and UV-induced skin 
carcinogenesis is the induction of the cyclooxygenase (COX) cascade (Figure 4).  
Chemical and UV exposure increases the phosphorylation of cytosolic phospholipase 
A2 which catalyzes the release of arachidonic acid from membrane phospholipids.  Free 
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arachidonic acid is then metabolized to prostaglandin H2 (PGH2) by prostaglandin H 
synthase, commonly known as COX.  COX exists as two different isoforms, COX-1 and 
COX-2.  COX-1 is constitutively expressed whereas COX-2 is inducible.  PGH2 is then 
metabolized by prostaglandin synthases to PGE2, PGD2, PGF2, prostacyclin (PGI2) and 
thromboxane A2.  Prostaglandins play a critical role in various physiological functions 
including wound healing, dilation/constriction of vascular smooth muscle, induction of 
labor, and blood clotting.  Furthermore, prostaglandins such as PGE2 play an important 
role in various pathological processes including cancer development.  PGE2 is produced 
by the metabolism of PGH2 by cytosolic PGES (cPGES), microsomal PGE Synthase-1 
(mPGES-1), and microsomal PGE Synthase-2 (mPGES-2).  PGE2 has been shown to 
promote abnormal cell growth and proliferation, angiogenesis, and tumor metastasis 
(reviewed in  Greenhough, et al., 2009). 
 
1.6 The role of COX-2/PGE2 signaling in skin carcinogenesis 
COX-1 is a house keeping gene expressed in most tissues and regulates gastric- 
and renal-homeostasis.  COX-2 on the other hand is an immediate-early gene product 
expressed in response to cytokines, growth factors, and various other stress-inducing 
factors.  There are various reports showing that the overexpression of COX-2 is 
involved in the promotion of several types of epithelial cell-derived cancers including 
colon, lung, breast, prostate, and skin ( Eberhart, et al., 1994; Wolff, et al., 1998; Gupta, 
et al., 2000; Kagoura, et al., 2001; Shim, et al., 2003).  These reports have led to both 
genetic and pharmacological approaches to validate the role of COX-2 in skin 
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carcinogenesis (Oshima, et al., 1996; Muller-Decker, et al., 2002; Muller-Decker and 
Furstenberger, 2007; Rundhaug, et al., 2007b).  For instance, Tiano et al. utilized the 
two-stage chemical carcinogenesis protocol in COX-1 and COX-2 knockout animals.  
COX-1 -/- mice displayed an approximate 30% decrease in tumor formation and COX-2 
-/- mice displayed an approximate 60% decrease in tumor formation in comparison to 
wild-type animals (Figure 5) (Tiano, et al., 2002).  COX deficient mice also displayed a 
decrease in proliferating keratinocytes and an increase in both keratin-1 (K1) and 
keratin-10 (K10), both early markers of keratinocyte differentiation, suggesting that 
inhibition of COX induces terminal differentiation.  In another study, Muller-Decker et al. 
demonstrated that transgenic mice that overexpress COX-2 develop more tumors than 
their wild-type counterparts when exposed to DMBA only (Muller-Decker, et al., 2002).  
These and many other reports highlight the importance of COX-2 in tumor development.  
In addition to using genetic approaches to understand the role of COX-2 in tumor 
development, pharmacological agents have also been employed.  For example, a 
clinical study reported that the selective COX-2 inhibitor, celecoxib, decreased the 
number of colorectal polyps formed in individuals with familial adenomatous polyposis 
disorder (Steinbach, et al., 2000).  Furthermore, diclofenac, a non-selective COX 
inhibitor, is an approved treatment for patients displaying actinic keratosis (small pre-
malignant lesion that has the potential to transform into an invasive NMSC) (Marks, et 
al., 1988; Berman, et al., 2009).  In an in vivo animal study, Oberyszyn et al. showed 
that topical application of celecoxib prevented UVB-induced skin tumorigenesis 
(Oberyszyn, et al., 2001).   
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Other studies show that the cyclooxygenase metabolic product, PGE2, is also 
increased in various animal and human tumors (Furstenberger, et al., 1989; Tiano, et 
al., 2002).  Ansari et al. reported that endogenous and exogenous PGE2 is sufficient to 
induce cell proliferation both in vivo and in vitro, suggesting that PGE2 can enhance 
tumor promotion (Ansari, et al., 2008).  PGE2 has also been shown to increase 
angiogenesis, tumor invasiveness, and metastasis (reviewed in Greenhough, et al., 
2009).  Given the adverse effects associated with COX-2 inhibitors, several groups 
proposed that inhibiting the synthesis of PGE2 by targeting its synthetic enzymes would 
be an effective approach to prevent cancer development.  Experimental observations 
revealed that out of the three PGES enzymes, only mPGES-1 regulates carcinogenesis 
(Kamei, et al., 2003; Kamei, et al., 2010).  Other studies show that mPGES-1 is 
overexpressed in colorectal adenomas and that genetic deletion of mPGES-1 reduces 
the number of preneoplastic aberrant crypt foci in mice (Yoshimatsu, et al., 2001; 
Nakanishi, et al., 2008).   
 Investigators have more recently identified an alternative novel therapeutic 
target; the E-type prostaglandin (EP) receptor.  Once PGE2 is produced, it is then 
exported out of the cell by a multidrug resistance-associated protein, MRP4, where it 
can act either in an autocrine or paracrine fashion to activate any of four EP receptors 
(EP1, EP2, EP3, and/or EP4).  The EP receptors are G-protein coupled receptors that 
contain seven transmembrane-spanning α helices, an extracellular N terminus, and an 
intracellular C terminus.  Each of the EP receptors are coupled to a different Gα subunit 
(Figure 6) where activation initiates downstream signaling via cAMP or phospholipase 
C.  Additionally, each receptor possesses distinct biochemical properties and 
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cellular/tissue localization.  The localization patterns of the EP receptors in the 
epidermis of SKH-1 mice after UV exposure has been described (Lee, et al., 2005).  
Under normal conditions, EP1 expression is low and localized throughout the stratum 
corneum.  After UV exposure, EP1 expression increases throughout the suprabasal 
layers.  Basal EP2 expression is low and is localized throughout the suprabasal layers.  
UV exposure increases its expression throughout the epidermis.  Both EP3 and EP4 
expression were undetectable under the experimental conditions tested.  
Strong evidence indicates that EP1, EP2, and EP4 activation is involved in tumor 
promotion.  Numerous studies have demonstrated that the upregulation of the EP1 
receptor promotes tumorigenesis while genetic or pharmacological inhibition of EP1 
receptors suppresses tumor formation (Watanabe, et al., 1999; Thompson, et al., 2001; 
Tober, et al., 2006; Surh, et al., 2011).  Similarly, EP2 and EP4 receptors are both 
reported to regulate epithelial tumor development.  A study showed that genetic deletion 
of the EP2 receptor, but not EP3, blocked DMBA/TPA-induced carcinogenesis in mice 
(Sung, et al., 2005).  In another study, EP4 receptor inhibition reduced aberrant crypt 
foci formation induced by azoxymethane or spontaneous polyp development in Min 
mice (Mutoh, et al., 2002).  These findings illustrate the role that the EP receptors play 
in tumor formation and identify novel therapeutic targets for the prevention/treatment of 
skin cancer.  
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1.7 Cancer chemoprevention by natural compounds 
  
The use of botanicals as therapeutic agents predates medical recorded history 
and has led to the identification of various natural compounds as chemopreventative 
and chemotherapeutic agents.  Several anticancer drugs that are used clinically were 
originally derived from plants including vincristine and vinblastine (derived from 
Catharanthus roseusI), paclitaxel and docetaxal (Taxus baccata or European yew), and 
etoposide (Podophyllum peltatu) (Nobili, et al., 2009).  Natural agents such as 
resveratrol and epigallocatechin gallate (EGCG), which is derived from green tea, are 
known to possess antioxidant and anti-inflammatory properties and may serve as a 
potential chemopreventive agent (Ahmed, et al., 2002; Kundu, et al., 2006).  
Development of natural compounds for preventing and treating cancer is an area of 
intense study as these agents are generally low in toxicity and safe to consume (Gupta 
and Mukhtar, 2002).   In addition, there is also growing evidence that the use of natural 
products as adjunctive therapy may produce synergistic effects when combined with 
current cancer treatments.  
 
1.8 Apigenin 
 
Apigenin (4’, 5, 7, - trihydroxyflavone), whose chemical structure is shown in 
Figure 6, is a natural plant flavone that is present in a variety of fruits and vegetables 
with the highest concentrations found in parsley and chamomile.  Apigenin has been 
used in alternative medicine for years to treat ailments ranging from asthma to neuralgia 
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and is now being evaluated for its chemopreventative potential.  In the last few years, 
significant progress has been made in determining the pharmacological effects of 
apigenin at the cellular and molecular level.  This non-mutagenic bioflavonoid displays 
several anticancer properties in tumor cells and also prevents skin tumorigenesis 
induced by UV light or DMBA/TPA (Figure 7) (Wei, et al., 1990; Birt, et al., 1997; Shukla 
and Gupta, 2010).  Previous data from our laboratory show that apigenin suppresses 
both TPA- and UVB-induced COX-2 expression in cultured keratinocytes (Van Dross, et 
al., 2005; Van Dross, et al., 2007).  Additional antitumor effects of apigenin have been 
attributed to features including its ability to activate tumor suppressor genes, induce cell 
cycle arrest, and initiate apoptosis (Lepley, et al., 1996; McVean, et al., 2000; Abu-
Yousif, et al., 2008; Kaur, et al., 2008; Choi and Kim, 2009).  
To begin to understand the role of COX-2 in the antitumor activity of apigenin we 
conducted a tumor study using the two-stage chemical carcinogenesis protocol and 
evaluated COX-2 expression, PGE2 production, and EP receptor expression in tumors 
and in the surrounding epidermis.  Apigenin suppressed DMBA/TPA-induced COX-
2/PGE2 signaling in the surrounding epidermis but did not alter COX-2/PGE2 signaling in 
the tumors.  Furthermore, apigenin increased chemically-induced terminal differentiation 
and decreased proliferation within the epidermis of the surrounding skin of tumor 
bearing animals.  We also demonstrate in this study that apigenin effectively blocks 
COX-2 expression and signaling in mouse skin acutely exposed to TPA.  Because 
suppression of COX-2 expression/activity prevents tumor development, the reduction in 
COX-2/PGE2 signaling that we observed here implies that apigenin blocks tumor 
development by inhibiting COX-2 expression, PGE2 production, and EP1 receptor 
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expression.  As such, apigenin or apigenin derivatives could provide additional options 
for treatment of various types of cancer including NMSC.   
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Figure 1: Anantomy of the human skin. Figure obtained from 
http://en.wikipedia.org/wiki/File:HumanSkinDiagram.jpg. 
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Figure 2: Histological examination of the structural layers within the epidermis.  Figure 
obtained from http://en.wikipedia.org/wiki/File:Epidermal_layers.png.  
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Table 1: Examples of tumor initiating and tumor promoting agents used in mouse skin 
tumorigenesis studies (DiGiovanni, 1992). 
.  
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Figure 3: The two-stage chemical carcinogenesis animal model.  Tumor initiation can 
be achieved with a single application of the chemical initiator, DMBA, to the dorsal skin.  
Next, tumor promotion occurs after repeated topical applications of the pro-inflammatory 
phorbol ester, TPA, which stimulates cell proliferation and clonal expansion of the 
initiated cell.  The final stage is progression.  Tumor progression occurs spontaneously 
and represents the point at which benign lesions transform to malignant tumors.  
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Figure 4: Prostaglandin E2 synthesis pathway.  Dermal exposure to pro-inflammatory 
agents such as TPA, leads to cPLA2 activation which catalyzes the release of 
arachidonic acid from membrane phospholipids.  Arachidonic acid is then metabolized 
to PGH2 by COX-2 and further metabolized to PGE2 by PGE Synthase 1 and 2.  PGE2 
plays a critical role in cancer formation by promoting cell proliferation, cell survival, and 
angiogenesis.    
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Figure 5: Genetic deficiency of COX-1 or COX-2 reduces tumorigenesis in the two-
stage chemical carcinogenesis protocol (adapted from (Tiano, et al., 2002).  In this 
experiment, F1 agouti wild-type and COX-deficient mice were subjected to DMBA-
initiated TPA-promoted skin tumorigenesis.  Tumor incidence decreased by 60% in 
COX-2 knockout mice and 30% in COX-1 knockout mice compared to wild-type, 
suggesting that COX-2 plays a role in skin tumor formation.  
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Figure 6: EP receptor signaling (adapted from Rundhaug, et al., 2011).  The four EP 
receptor subtypes are G-protein-coupled receptors that are activated by PGE2.  EP1 is 
a Gq-coupled receptor that activates phospholipase C (PLC), resulting in the production 
of 1, 2-diacylglycerol (DAG) and inositol 1, 4, 5-trisphosphate (IP3).  DAG activates 
protein kinase C (PKC) and IP3 increases [Ca2+].  Both EP2 and EP4 are Gs-coupled 
receptors that activate adenylyl cyclase (AC) and increase both cAMP synthesis and 
protein kinase A (PKA).  EP3 is a Gi-coupled receptor that reduces cAMP levels upon 
activation.  Activation of EP1, EP2, and EP4 receptors have all been shown to promote 
skin tumor formation by increasing cell proliferation, angiogenesis, and cell survival.   
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Figure 7: Apigenin inhibits DMBA/TPA-induced skin tumor formation (obtained from 
Birt, et al., 1997).  Female SENCAR mice were exposed to a single dose of DMBA.  
Animals were pretreated with apigenin (5 or 20 µmol) or DMSO (vehicle control) before 
TPA exposure twice a week for 20 weeks and tumor development evaluated up to week 
40.  Apigenin inhibited skin tumor formation in a concentration dependent fashion.  
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Figure 8: Structure of apigenin (4’, 5, 7, - trihydroxyflavone). 
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Chapter 2 
Material & Methods 
 
2.1 Materials and reagents  
 Apigenin was purchased from Indofine Chemical Company (Hillsborough, NJ).  
Acetone, dimethyl sulfoxide (DMSO), and TPA were purchased from Sigma-Aldrich (St. 
Louis, MO).  PGE2 EIA kits as well as COX-2, EP receptor, mPGES-1, and mPGES-2 
antibodies were from Cayman Chemical (Ann Arbor, MI).  Anti-active caspase-3 
antibody was from BD Biosciences (Chicago, IL).  Ki67 antibody was purchased from 
Abcam (Cambridge, MA).  Keratin-1 (K1) and -10 (K10) antibodies were purchased from 
Covance (Princeton, NJ).   
2.2  Animals 
 
SKH-1 hairless mouse breeding pairs were generously provided by Dr. Susan M. 
Fischer (MD Anderson Cancer Center; Smithville, TX).  Animals were bred and 
maintained within the Department of Comparative Medicine of East Carolina University.  
Room temperature of the housing unit was maintained at 70-75°F with 40-60% humidity 
and on a 12 hour light/dark cycle.  Water and food were provided ad libitum.  The mice 
were fed a bioflavonoid-free diet (AIN-76A; Dyets, Bethelham, PA) one week prior to 
experimentation.  All experimental procedures used for this study were approved by the 
Institutional Animal Care and Use Committee of East Carolina University. 
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2.3  Breeding and genotyping SKH-1 mice 
 
SKH-1 hairless mouse breeding pairs consisted of one pair COX-2 wild-type (COX-2 
+/+) and one pair COX-2 heterozygous (COX-2 +/-).  Animals were bred to produce only 
wild-type and heterozygous mice.  COX-2 homozygous (COX-2-/-) knockout mice 
develop renal failure and survive only a few weeks after birth and therefore were not 
bred.  SKH-1 pups were weaned from the mothers at approximately 21 days after birth.  
At this time, each mouse was ear tagged and tail snipped.  Individual tail snips were 
added to 100 µl of tail digestion buffer (TDB) consisting of; 50 mM KCl, 10 mM Tris-Hcl 
(pH 9), 0.1% Triton-X, and 0.4 mg/ml proteinase K).  Samples were then incubated 
overnight at 55°C.  Upon digestion, samples were incubated at 94°C for 10 minutes to 
inactivate proteinase K. Samples were then centrifuged at top speed for 15 minutes.  
Next, 1.0 µl of genomic DNA was placed into the following PCR mixture:  5 µl 10x PCR 
buffer, 10 mM dNTP mixture, 50 mM MgCl2, 10 µM primer, 0.5 µl Taq polymerase 
(Invitrogen), and sterile dH2O.  The following set of primers was used to validate SKH-1 
COX-2 wild-type allele; forward-COX2 WT: ACACACTCTATCACTGGCACC, reverse-
COX-2: ATCCCTTCACTAAATGCCCTC.  The following set of primers was used to 
validate SKH-1 COX-2 heterozygous allele; forward-COX2 WT: 
ACGCGTCACCTTAATATGCG, reverse-COX-2: ATCCCTTCACTAAATGCCCTC.  The 
following GAPDH primers were used to validate the PCR reaction; forward-GAPDH: 
TGCACCTCTGGTAACTCCGC, reverse-GAPDH: GCATCACCTGGCCTACAGGA.  
Samples were then placed into a thermal cycler and incubated at 95°C for 3 minutes to 
denature the template followed by 25-35 cycles of PCR amplification.  Once complete, 
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amplified PCR products were analyzed by agarose gel electrophoresis and visualized 
by ethidium bromide staining.   
 
2.4 Two-stage chemical carcinogenesis protocol 
 
Female SKH-1 mice ranging from 5 to 10 weeks of age were used (n = 19 per 
treatment group).  Female mice were used to prevent fighting/injury to one another as 
they tend to be docile compared in comparison to males.  All animals received a single 
initiating dose of 100 nmol of DMBA topically applied in 200 µl of acetone using a non-
abrasive swab (Texwipe, Mahwah, NJ).  One week after initiation, all animals received 
twice weekly applications of 3.2 nmol of TPA in 200 µl of acetone for 25 weeks.  
Apigenin was applied topically at 5 µmol and 20 µmol in 200 µl of DMSO one hour prior 
to TPA exposure.  Concentrations of apigenin were determined from the work of Diane 
Birt (Wei, et al., 1990).  Animals in the control group were pretreated with DMSA 
(vehicle control) one-hour prior to TPA application.  After 25 weeks of treatments, 
animals were euthanized via cervical dislocation and CO2 asphyxiation.  Subsequently, 
tumors and surrounding skin were measured in two dimensions (length x width) using 
digital calipers and then harvested and analyzed by a board certified pathologist, Dr. 
Allan Smith.  Tumors and surrounding skin were then labeled and stored in skin fixative 
(Amersco, Solon, OH) or frozen in liquid nitrogen.  Statistical analysis for tumor 
incidence and tumor multiplicity was conducted using repeated measure ANOVA with 
GraphPad Prism Software (La Jolla, CA) and Microsoft Excel 2010 (Mission Viejo, CA). 
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2.5 Immunohistochemistry 
Fixed epidermal skin and tumors were incubated overnight in a 40% sucrose 
solution before being embedded in TissueTek OCT compound (Sakura Finetek, 
Torrence, CA), sectioned, and mounted on positively charged slides.  The tissues were 
blocked and incubated in 3.0% H2O2 for 30 minutes to quench endogenous peroxidase 
activity.  Sections were then incubated overnight with primary antibody and were 
incubated with secondary antibody for 30 minutes.  Preliminary experiments were 
conducted to optimize conditions for primary antibody concentrations.  Staining was 
visualized using the VectaStain ABC kit (Burlingame, CA) and diaminobenzidine (DAB) 
(Sigma, St. Louis, MO) and the tissues counterstained in Harris’ hematoxylin.  
Quantification of optical densities was measured from non-counterstained sections of 
the epidermis at 40x magnification and at 4x for tumor samples.  Color images from 10 
random fields showcasing the epidermis were captured using ImagePro software under 
identical exposure conditions.  Each image captured was then background corrected to 
a control slide and converted to an 8-bit gray scale picture before analyzing the 
densities using the software.  Color images of random whole tumor samples were 
captured and processed as described above.  Statistical analysis was completed using 
one-way ANOVA and Student’s T-test using GraphPad Prism software (La Jolla, CA) 
and Microsoft Excel 2010 software (Mission Viejo, CA). 
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2.6 Western analysis 
The dorsal skin from  SKH-1 mice in each experimental group was scraped, 
pooled (n = 3) and homogenized in a buffer containing 60 mM Tris pH 8.6, 5 mM EDTA, 
5 mM EGTA, 300 mM sucrose, 1% NP-40, 5 mM DTT, 2 mM PMSF, 10 mM sodium 
molybdate, 20 µg/ml aprotinin, 20 mM sodium fluoride, and 100 mM sodium 
orthovanadate.  Epidermal extracts were then centrifuged at 3000 x g for 10 minutes 
and the supernatant collected for determination of protein concentration using the BCA 
method (Thermo Scientific, Rockford, IL).  Proteins were resolved in SDS-PAGE gels, 
protein transferred to PVDF membranes, and blots probed with the appropriate primary 
and secondary antibody.  Preliminary experiments were conducted to optimize 
conditions for antibody concentrations.  Bands were visualized on X-ray film using 
Enhanced ChemiLuminesence reagents (Amersham, Piscataway, NJ) according to the 
manufacturer’s protocol.  The intensity of each band was determined using Image J 
image Processing and Analysis Software (http://rsbweb.nih.gov/ij/).      
 
2.7 PGE2 assays 
For PGE2 analysis of the surrounding skin and tumors, epidermis from tumor 
bearing mice was isolated and prostaglandins extracted as described by Fisher et al 
(Fischer, et al., 2007). Briefly, the epidermis was removed and homogenized in Tris 
buffer containing 5 µg/ml of indomethacin.  For the PGE2 assays of tumor samples, 
random tumors from each treatment group were selected.  Tumors were minced and 
homogenized in Tris buffer containing 5 µg/ml of indomethacin.  Samples were then 
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centrifuged at 3000 x g for 10 minutes, and an aliquot of the extract removed for protein 
concentration determination.  Lysates were then acidified using HCl and applied to a 
preconditioned C18 SPE cartridge (Grace Davison Discovery Science, Deerfield, IL).  
Columns were then rinsed with 15% ethanol to remove any polar substances.  
Afterwards, columns were rinsed with petroleum ether (Sigma-Aldrich, St. Louis, MO) to 
remove all traces of water and to allow PGE2 molecules to adhere to the silica in the 
column.  Methyl formate (Sigma-Aldrich, St. Louis, MO) was then used to elute PGE2 
from the column and then PGE2 was dried under a gentle stream of nitrogen gas.  
Samples were reconstituted in EIA immunoassay buffer provided by the manufacturer.  
PGE2 concentrations were then determined by ELISA as directed by the manufacturer 
(Cayman, Ann Arbor, MI).  Statistical analysis was computed using GraphPad Prism 
Software (La Jolla, CA) and Microsoft Excel 2010 (Mission Viejo, CA).  
 
2.8 Statistical Analysis 
Data is presented as mean ± SD.  Repeated analysis of variance (ANOVA), 
Tukey post-hoc analysis, and Student’s T-test was carried out using GraphPad Prism 
and Microsoft Excel 2010.  
 
Chapter 3 
Results 
Aim 1: Acute Effects of Apigenin on TPA-mediated COX-2 Expression in Mouse 
Epidermis 
3.1 Apigenin inhibits TPA-mediated COX-2 expression in an acute setting in the 
epidermis of SKH-1 mice 
 
Previous reports from our laboratory show that apigenin reduces TPA- and UVB-
induced COX-2 expression and PGE2 production in cultured keratinocytes (Van Dross, 
et al., 2005; Tong, et al., 2007; Van Dross, et al., 2007).  To determine the optimal 
conditions for the induction of COX-2 in the epidermis, different concentrations of TPA 
were applied to the dorsal surface of SKH-1 mice and the skin isolated after 8 hours.  
Western blot analysis showed that TPA caused a 1.9-, 4.4-, and a 4.7-fold increase in 
COX-2 protein expression when compared to vehicle-treated epidermis (Figure 9A).  
Because topical application of 3.4 nmol and 6.8 nmol TPA produced a similar fold 
increase in COX-2 expression, 3.4 nmol of TPA was used throughout this study.  Next, 
a time course analysis of COX-2 induction was conducted by topically treating animals 
with 3.4 nmol TPA or with vehicle for 2, 4, or 8 hours (Figure 9B).  TPA caused a 4.0-
fold increase in epidermal COX-2 expression at 8 hours.  A modest increase in COX-2 
expression was observed in animals treated with TPA for 2 and 4 hours.  
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Next, our goal was to confirm that TPA-induced COX-2 expression is reduced in 
COX-2 heterozygous knockout mice (COX-2 +/-) compared with wild-type (COX-2 +/+) 
mice.  In Figure 10A, different concentrations of TPA were applied to the dorsal surface 
of SKH-1 COX-2 +/+ and SKH-1 COX-2 +/- mice and the skin isolated after 8 hours.  
Western blot analysis revealed no difference in COX-2 expression between the 
genotypes.  Also, in our time course study, differences in the expression of COX-2 in 
COX-2 +/+ and COX-2 +/- mice were not observed (Figure 10B).  Based on these 
results, the COX-2 +/- animals were excluded from this study.  
 
Next, we wanted to determine the effect of apigenin on TPA-induced COX-2 
expression, PGE2 production, and EP receptor expression in vivo.  Apigenin was 
topically applied to mouse skin 1 hour prior to the application of TPA and epidermal 
COX-2 expression measured by Western analysis (Figure 11A).  Our data show that 
apigenin suppressed TPA-induced COX-2 expression in a concentration-dependent 
manner.  Further, the level of expression of COX-2 in animals treated with TPA plus 20 
µmol apigenin (TPA + AP20) was comparable to the level of COX-2 present in the 
epidermis of animals treated with vehicle or apigenin alone.  Next, we conducted 
immunohistochemical analysis to examine the distribution (Figure 11B) and to quantify 
the relative expression of COX-2 (Figure 11C) in the skin.  Similar to other reports, TPA 
increased COX-2 expression in each epidermal layer with the most prominent staining 
located in the basal layer (Tripp, et al., 2003; Funk, et al., 1993).  Apigenin at 5 and 20 
µmol dramatically reduced TPA-induced COX-2 expression throughout the epidermis.  
Also, COX-2 expression was absent in vehicle treated skin and skin treated with 
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apigenin alone.  These findings show that apigenin restores basal level COX-2 
expression in TPA-exposed epidermis.  
 
3.2 Apigenin inhibits TPA-mediated PGE2 production in the mouse epidermis.  
To determine if apigenin also blocks PGE2 production in vivo, mice were topically 
treated with TPA, TPA plus apigenin, apigenin or vehicle and PGE2 levels measured 
(Figure 12A).  As anticipated, TPA increased PGE2 production.  Pretreatment of the 
epidermis with 5 or 20 µmol apigenin blocked TPA-induced PGE2 synthesis with both 
concentrations of apigenin producing a statistically significant decrease in PGE2 
production.  The synthesis of PGE2 is dependent on the sequential enzymatic activity of 
COX and PGES.  To determine if apigenin inhibits TPA-induced PGE2 production by 
decreasing mPGES expression, epidermal mPGES levels were measured by Western 
analysis (Figure 12B).  The steady-state levels of mPGES-1 or mPGES-2 were not 
changed by TPA and mPGES-1 and mPGES-2 were only slightly altered in animals 
treated with TPA plus 20 µmol apigenin.  These findings that apigenin does not inhibit 
PGE2 by blocking the expression of mPGES1 or mPGES2. 
 
3.3 Apigenin decreases EP1 receptor expression in TPA-treated mouse skin 
 
In Figure 13, we analyzed the expression of each EP receptor in the epidermis 
using Western analysis.  A 3-fold increase in EP1 receptor expression was observed in 
mice topically treated with TPA.  Apigenin suppressed the TPA-induced increase in EP1 
receptor expression in a concentration-dependent manner.  Next, we examined the 
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expression of the EP2 receptor which appears as two separate bands on the Western 
blot likely due to post translational modification of the receptor.  In each treatment 
group, no significant changes were observed in EP2 receptor expression.  In contrast, 
no consistent pattern of EP3 and EP4 receptor expression was observed in any of the 
treatment groups.  We also examined the expression of EP receptors in cultured 
keratinocytes.  Interestingly, EP1 receptor expression was elevated in the tumorigenic 
JWF-2 cell line while the expression of this receptor was barely detectable in non-
tumorigenic HaCaT cells.  Expression of only the high molecular weight form of the EP2 
receptor was observed in JWF2 cells while the level of each EP2 receptor band in 
HaCaTs was similar to the levels found in epidermal extracts.  On the other hand, JWF2 
and HaCaT cells did not express the EP4 receptor.  Thus, the EP1 receptor displays a 
similar expression pattern in TPA-treated epidermis and in cultured tumorigenic 
keratinocytes. 
 
Next, we conducted immunohistochemical analysis to examine the expression 
and distribution of the EP receptors in the epidermis following exposure to TPA and 
apigenin (Figure 14).  Topical application of TPA increased EP1 receptor expression in 
each epidermal layer with the highest intensity staining in the suprabasal epidermis.  In 
agreement with our data from the epidermal lysates, apigenin suppressed TPA-induced 
EP1 receptor expression.  EP2 receptor expression was intense in each treatment 
group with a slight increase in EP2 expression in the outermost layers of the epidermis 
in TPA-treated mice.  In contrast, EP3 and EP4 expression were barely detectible in 
each treatment group.  These results show that apigenin suppresses TPA-mediated 
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EP1 induction and this pattern of expression is consistent with an inhibitory effect on 
tumor formation.  Overall, apigenin inhibits TPA-mediated COX-2/PGE2 signaling 
pathway in an acute setting.  
 
Aim 2: Apigenin Inhibits Chemically-induced Tumorigenesis; Role of COX-2/PGE2 
Signaling and the EP1 Receptor Expression in Non-melanoma Skin Cancer 
 
3.4 Apigenin inhibits DMBA/TPA-induced carcinogenesis in SKH-1 mice 
 To investigate the chemopreventative activity of apigenin, the two-stage chemical 
carcinogenesis protocol was utilized.  Female SKH-1 mice were exposed to a single 
topical application of 100 nmol DMBA followed by twice weekly applications of 3.2 nmol 
of TPA for 25 weeks.  One hour prior to TPA exposure, animals were topically treated 
with 5 µmol apigenin (AP5 + DMBA/TPA), 20 µmol apigenin (AP20 + DMBA/TPA), or 
vehicle/DMSO (DMBA/TPA).  In animals treated with DMBA/TPA alone, approximately 
70% of the mice developed tumors 25 weeks post-initiation (Figure 15).  Animals in the 
AP5 + DMBA/TPA group displayed an approximate 35% decrease in tumor incidence at 
the same time point.  In the AP20 + DMBA/TPA treatment group, tumor incidence was 
significantly reduced (p< 0.05) and tumor development delayed by 3 weeks compared 
with DMBA/TPA-treated animals.  In addition, the average number of tumors per mouse 
in AP20 + DMBA/TPA- compared with DMBA/TPA-exposed animals was significantly 
decreased (0.18 and 3.37 respectively).  In Table 2, tumors were measured and 
categorized according to their size to determine the effect of apigenin on tumor size.  
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More than 50% of the tumors obtained from the animals in the DMBA/TPA treatment 
group were 5 mm2 or greater with successively decreasing numbers of tumors in the 2.5 
- 4.9 mm2 and 0.1 – 2.4 mm2 size categories.  A similar tumor distribution is also 
observed in both apigenin 5 and 20 µmol groups.  Overall, apigenin significantly 
decreased tumor incidence and multiplicity in DMBA/TPA treated animals but did not 
change the tumor size distribution.  Furthermore, apigenin at both concentrations had 
no significant effect on body weight in comparison to DMBA/TPA treated animals 
(Figure 16).   
 
3.5 Apigenin blocks COX-2 expression and PGE2 production in the surrounding 
epidermis 
Numerous studies show that COX-2 promotes tumorigenesis and that the 
inhibition of COX-2 decreases tumor formation.  Birt et al determined that apigenin 
prevents tumor development and work from this laboratory has shown that apigenin 
blocks COX-2 expression and activity in cultured keratinocytes (Birt, et al., 1997; Van 
Dross, et al., 2005; Tong, et al., 2007; Van Dross, et al., 2007).  Therefore, we 
examined COX-2 expression and activity in isolated tumors and in the tissue 
surrounding the tumors (referenced throughout as surrounding epidermis) to further 
investigate the chemopreventative properties of apigenin and whether they are related 
to the inhibition of COX-2 expression.  In the surrounding epidermis, apigenin at both 5- 
and 20-µmol significantly suppressed DMBA/TPA-induced COX-2 expression 
throughout the epidermis Figure 17A).  In addition, we observed strong COX-2 
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expression at the epidermal-dermal interface that was not decreased by apigenin at 
either concentration.  In Figure 17B, we examined COX-2 expression in isolated tumors 
from each treatment group.  Our data show that COX-2 expression is elevated in all of 
the tumors isolated from the DMBA/TPA, AP5 + DMBA/TPA, and AP20 + DMBA/TPA 
treatment groups demonstrating the importance of COX-2 expression in tumor 
development.  
 
The COX-2 metabolic product PGE2 is known to play a prominent role in tumor 
promotion.  As such, we examined PGE2 production in the surrounding epidermis 
(Figure 17C) and tumors (Figure 17D).  In the surrounding epidermis, apigenin inhibited 
DMBA/TPA-induced PGE2 production in a concentration-dependent fashion (p < 0.05 
for AP20 + DMBA/TPA).  In tumors, PGE2 production was not decreased by 5- or 20-
µmol apigenin.  These results show that apigenin inhibits COX-2 expression and activity 
in the surrounding epidermis but not in developed tumors.   
 
3.6 Apigenin decreases EP1 and EP2 receptor expression in the surrounding epidermis 
PGE2 produces its cellular effects by interacting with EP receptors that are 
expressed in various tissues including the epidermis.  Both TPA and UV-light are known 
to upregulate EP receptor expression (Tober, et al., 2006; Black, et al., 2008).  In Figure 
18, we analyzed EP1 and EP2 receptor expression in the surrounding epidermis and 
tumors of animals in each of our treatment groups.  In the surrounding epidermis, 
apigenin at 5- and 20-µmol significantly inhibited DMBA/TPA-induced EP1 expression 
throughout the epidermal layers (Figure 18A).  In contrast, EP1 expression in isolated 
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tumors from the DMBA/TPA, AP5 + DMBA/TPA, and AP20 + DMBA/TPA treatment 
groups was strongly expressed throughout the epidermis (Figure 18B).  Figure 18C 
shows that AP20 + DMBA/TPA significantly inhibited EP2 receptor expression in the 
surrounding epidermis; however, apigenin did not decrease EP2 expression in 
DMBA/TPA-induced tumors (Figure 18D).  Overall, these results show that apigenin 
suppresses DMBA/TPA-induced EP1 and EP2 expression in the surrounding epidermis 
but not in existing tumors.  These findings are consistent with other reports which 
demonstrate that EP receptor inhibition effectively prevents tumor formation (Kawamori, 
et al., 2001; Kawamori, et al., 2005; Tober, et al., 2006). 
 
3.7 Apigenin’s effect on epidermal differentiation and proliferation 
 
 In the epidermis, the basal layer represents the proliferative zone of 
keratinocytes.  Once basal cells divide, a daughter cell moves upward to the squamous 
layer where cytokeratins that are needed for terminal differentiation are expressed.  
Keratin-1 (K1) and keratin-10 (K10) are two critical cytokeratins expressed in the early 
phases of terminal differentiation.  K1 and K10 are normally expressed in the 
suprabasal epidermis and not in basal keratinocytes which have proliferative capacity.  
K1 and K10 form a heterodimer whose interaction in a 1:1 ratio is critical for its function 
to maintain the structural integrity of keratinocytes.  Thus, expression of K1 and K10 in 
the basal keratinocytes indicates a loss in proliferative capacity and premature entry into 
the terminal differentiation program.  In the surrounding epidermis obtained from 
DMBA/TPA treated animals, K1 staining is predominantly located in the suprabasal 
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layers (Figure 19A).  In contrast, the surrounding epidermis of AP5 + DMBA/TPA- and 
AP20 + DMBA/TPA-treated animals contained numerous K1 positive basal 
keratinocytes.  Moreover, in AP20 + DMBA/TPA treated animals, the intensity of K1 
expression was significantly increased.  A similar staining pattern was observed for K10 
with prominent suprabasal signal in the surrounding epidermis of DMBA/TPA animals 
and K10 positive basal and suprabasal keratinocytes in apigenin + DMBA/TPA treated 
animals (Figure 19C).  Also, apigenin significantly increased K10 expression intensity 
within the epidermis.  In tumors (Figure 19B), K1 staining was limited to the suprabasal 
region and was not observed in the basal epidermal cell layer in DMBA/TPA treated 
animals and apigenin increased K1 expression throughout the tumors.  In Figure 19D, 
K10 expression was elevated in DMBA/TPA-treated animals but decreased in the 
presence of apigenin.  These data show that apigenin increases K1 and K10 expression 
in the surrounding epidermis of mice treated with DMBA/TPA.  These findings suggest 
that apigenin may prevent tumor development by increasing terminal differentiation.  
   
 
Keratinocyte proliferation is known to be induced by TPA and PGE2 
(Furstenberger and Marks, 1980; Pentland and Needleman, 1986).  Therefore we 
investigated the effect of apigenin on keratinocyte proliferation.  Figure 20 shows the 
expression of Ki67, a proliferation marker, in the surrounding epidermis and tumors of 
the animals from each of our treatment groups.  In the surrounding epidermis, 
DMBA/TPA-induced Ki67 expression was inhibited in animals treated with 5- or 20-µmol 
apigenin (Figure 20A).  Similarly in isolated tumors, apigenin reduced the number of 
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Ki67 positive cells (Figure 20B).  These data imply that the apigenin-mediated decrease 
in COX-2/PGE2 signaling may alter induce cells to switch from a proliferating state to a 
differentiating state.  
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Figure 9: Concentration and time course analysis of TPA-induced COX-2 expression in 
mouse epidermis.  (A) SKH-1 mice (n = 3) were topically treated with 1.7, 3.4, or 6.8 
nmol of TPA dissolved in acetone or mice were treated with acetone alone (vehicle; 
VEH).  Animals were euthanized after 8 hours and the epidermis was isolated.  
Epidermal extracts were then pooled and protein concentration was determined as 
described in the material and methods section.  Western blot analysis was carried out 
with antibodies directed towards COX-2 and GAPDH (loading control).  (B) Time-
dependent induction of COX-2 protein expression by TPA.  Mice were treated topically 
with 3.4 nmol TPA and euthanized after 2, 4, or 8 hours.  Western analysis was carried 
out using antibodies directed towards COX-2 or GAPDH.  Fold induction (FI) in TPA-
treated samples compared to time-matched vehicle treated samples is indicated below 
the figure.  
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Figure 10: Concentration and time course analysis of TPA-induced COX-2 expression 
in COX-2 WT and COX-2 HET mouse epidermis.  (A) Both COX-2 +/+ and COX-2 +/- 
mice were topically treated with 1.7 or 3.4 nmol of TPA dissolved in acetone or mice 
were treated with acetone alone (vehicle; VEH).  Animals were euthanized after 8 
hours, the epidermis isolated, pooled (n = 3) and Western analysis carried out with 
antibodies directed towards COX-2 and GAPDH (loading control).  (B) Time-dependent 
induction of COX-2 protein expression by TPA.  COX-2 +/+ and COX-2 +/- mice were 
treated topically with 3.4 nmol TPA and euthanized after 2, 4, or 8 hours.  Western 
analysis was carried out using antibodies directed towards COX-2 or GAPDH.  Fold 
induction (FI) in TPA-treated samples compared to time-matched vehicle treated 
samples is indicated below the figure.  
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Figure 11: Apigenin inhibits TPA-induced COX-2 expression in the epidermis of SKH-1 
mice.  SKH-1 mice (n = 3) were topically treated with 20 µmol apigenin (API), 3.4 nmol 
TPA (TPA), 3.4 nmol TPA + 5 µmol apigenin (TPA + AP5), 3.4 nmol TPA + 20 µmol 
apigenin (TPA + AP20), or vehicle (VEH).  Animals were euthanized after 8 hours and 
the epidermis isolated.  (A) Western analysis was carried out using antibodies directed 
towards COX-2 and GAPDH.  Fold induction (FI) of TPA- or TPA + Apigenin-treated 
samples compared to the vehicle-treated sample is indicated below the figure.  (B) 
Epidermal sections from mice treated as indicated above were analyzed for COX-2 
protein content by immunohistochemical analysis.  Tissue sections were observed at 
40X magnification and (C) mean optical density of 10 images (n = 3) calculated using 
ImagePro software (ǂ p < 0.05 TPA compared to vehicle, * p < 0.05 apigenin compared 
to TPA, data presented as mean ± SD). 
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Figure 12: Apigenin inhibits TPA-mediated COX-2 activity in the mouse epidermis.  (A) 
Mice were topically treated as described in Figure 16.  Epidermal PGE2 levels were 
assessed by conducting ELISA analysis as directed by the manufacturer.  Statistical 
analysis was conducted using one-way ANOVA and Student’s T-test (ǂ p < 0.05 TPA 
compared to vehicle, * p < 0.05 apigenin compared to TPA).   (B) Effect of apigenin on 
mPGES expression.  Animals were treated as indicated above.  mPGES-1 and 
mPGES-2 expression was evaluated by Western blot analysis.  Fold induction (FI) of 
TPA- or TPA + Apigenin-treated samples compared to the vehicle-treated sample is 
indicated below the figure.   
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Figure 13:  Apigenin inhibits TPA-mediated expression of the EP1 receptor in the 
epidermis.  SKH-1 mice were topically treated as described previously.  Western blot 
analysis was carried out using antibody directed towards EP1, EP2, EP3, and EP4 
receptors.  Cell lysates from untreated JWF-2 and HaCaT cell lines were also loaded in 
the SDS-PAGE gel.  GAPDH was measured to confirm equal loading of cell lysates.  
Fold induction (FI) of TPA- or TPA plus apigenin-treated samples compared to the 
vehicle-treated sample is indicated below the figure.   
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Figure 14:  Examination of EP receptor expression and localization in the epidermis.  
SKH-1 mice were treated with 20 µmol apigenin (API), 3.4 nmol TPA (TPA), 3.4 nmol 
TPA + 20 µmol apigenin (TPA + AP20), or vehicle (VEH).  Frozen epidermal sections    
(n = 3) were analyzed for (A) EP1, (B) EP2, (C) EP3, and (D) EP4 expression by 
immunohistochemistry as described in Materials and Methods (* p < 0.05 in comparison 
to TPA treated animals). 
.  
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Figure 15:  Apigenin inhibits chemically-induced tumorigenesis in SKH-1 female mice.  
A single topical application of 100 nmol of DMBA was applied to the dorsum of SKH-1 
mice to achieve tumor initiation.  One-hour prior to TPA exposure animals were treated 
with apigenin at 5 µmol (AP5 + DMBA/TPA) or 20 µmol (AP20 + DMBA/TPA) twice 
weekly for 25 weeks.  Tumors were counted on a weekly basis.  AP20 + DMBA/TPA 
significantly reduced (A) the percentage of animals bearing tumors (tumor incidence) at 
24 and 25 weeks post-initiation, and (B) the number of tumors per animal (tumor 
multiplicity) at 23-25 weeks post-initiation.  (C) Representative images from each 
treatment group.  Statistical analysis was conducted using repeated measure ANOVA 
with Tukey’s post-hoc analysis (* p < 0.05). 
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Figure 16: Weekly analysis of animal weight by treatment group throughout the two-
stage chemical carcinogenesis protocol.  Apigenin at both concentrations had no 
significant effect on body weight throughout the study.   
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Table 2: Comparison of tumor sizes for each treatment group.  At the conclusion of the 
tumor study, the size of each tumor was measured in two dimensions (length x width) 
using a digital caliper.  Tumors from each treatment group (n = 19) were then 
categorized according to size (listed as mean ± SD) and compared.  Statistical analysis 
was conducted using one-way ANOVA and Student’s T-test analysis (* p < 0.05 
apigenin compared to DMBA/TPA, ǂ p < 0.05 AP20 + DMBA/TPA to AP5 + 
DMBA/TPA).  
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Figure 17: Examination of apigenin’s effect on COX-2 expression and PGE2 production 
in the surrounding epidermis and in tumors.  Animals were subjected to the two-stage 
chemical carcinogenesis protocol as described in the methods section.  (A) Samples of 
the surrounding epidermis and (B) tumors from DMBA/TPA, AP5 + DMBA/TPA, and 
AP20 + DMBA/TPA were analyzed for COX-2 expression by immunohistochemistry and 
optical densities were determined using ImagePro software.  Epidermal PGE2 levels 
were assessed in the (C) surrounding epidermis and (D) tumor samples from each 
treatment group by conducting ELISA analysis as directed by the.  Tissue sections were 
observed at 40x for the surrounding epidermis and 20x for tumors (optical densitometry 
performed at 4x for tumors only).  Asterisk indicates statistical significance (* p < 0.05 
compared to the DMBA/TPA treatment group). 
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Figure 18: Apigenin suppresses DMBA/TPA-mediated EP1 and EP2 receptor 
expression throughout the epidermis.  Frozen epidermal sections (A & C) and tumors (B 
& D) were analyzed for EP1 and EP2 receptor expression and optical densities were 
determined using ImagePro software.  Tissue sections were observed at 40x for normal 
skin and 20x for tumor (optical densitometry performed at 4x for tumors only).  Asterisk 
indicates statistical significance (* p < 0.05 compared to DMBA/TPA treatment group). 
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Figure 19: Apigenin increases keratin-1 (K1) and keratin-10 (K10) expression 
throughout the epidermis.  Frozen epidermal sections (A & C) and tumors (B & D) from 
each treatment group were subjected to immunohistochemical analysis using antibodies 
towards K1 and K10 as described previously.  Tissue sections were observed at 40x for 
normal skin and 20x for tumor (optical densitometry performed at 4x for tumors only).  
Asterisk indicates statistical significance (* p < 0.05 compared to DMBA/TPA treatment 
group).   
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Figure 20: Apigenin inhibits keratinocyte proliferation in surrounding epidermal tissue 
and in tumors.  Frozen sections from DMBA/TPA, AP5 + AMBA/TPA, or AP20 + 
DMBA/TPA treated animals were analyzed for Ki67.  The number of Ki67 positive cells 
per micrometer (µm) of basal epidermis was counted in the (A) surrounding epidermis 
and (B) in tumors.  Tissue sections were observed at 40x for normal skin and 20x for 
tumor.  Asterisk indicates statistical significance (* p < 0.05 compared to DMBA/TPA 
treatment group). 
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Chapter 4 
Discussion 
Apigenin is natural plant flavonoid that inhibits both DMBA/TPA- and UVB-
induced skin tumor formation.  In addition, numerous laboratories have reported that 
apigenin also blocks breast, colon, and prostate tumorigenesis (Wang, et al., 2000; 
Gupta, et al., 2002; Van Dross, et al., 2003; Way, et al., 2004; Au, et al., 2006; Shukla, 
et al., 2007; Choi and Kim, 2009).  However, the exact mechanism by which this occurs 
is unclear.  In this proposal we found that apigenin inhibited DMBA/TPA-induced mouse 
skin tumor promotion and chemically-induced COX-2 expression and activity in the 
epidermis of SKH-1 mice.  We also showed that apigenin decreases DMBA/TPA-
mediated induction of EP1 and EP2 receptors.  Furthermore, we determined that the 
apigenin-regulated decrease in COX-2/PGE2 signaling occurred coincident with an 
increase in terminal differentiation and decrease in keratinocyte proliferation.  We also 
demonstrated in acute exposure studies that apigenin inhibits TPA-induced COX-2 
expression, PGE2 production, and EP receptor expression in the mouse epidermis.  
These findings suggest that apigenin blocks COX-2 expression and signaling in 
DMBA/TPA treated animals resulting in an induction of terminal differentiation which 
ultimately inhibits tumor development.  
Our major goal in this study was to determine if apigenin inhibits chemically-
induced tumor formation in SKH-1 mice by blocking COX-2/PGE2 signaling.  Our results 
clearly show that apigenin significantly decreases tumor multiplicity and tumor incidence 
in animals subjected to the DMBA/TPA chemical carcinogenesis protocol.  We also 
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determined that apigenin decreases epidermal COX-2 expression, PGE2 production, 
and EP receptor expression.  Other groups have shown that the inhibition of COX-2 by 
genetic deletion or pharmacological inhibition leads to a decrease in skin tumor 
formation.  For instance, Fischer et al. reported that heterozygous COX-2 knockout 
mice displayed a 50-65% reduction in tumor incidence compared to wild-type mice 
when subjected to the UV-light tumorigenesis protocol (Fischer, et al., 2007).  In another 
study, a 75% decrease in tumor incidence was observed in homozygous COX-2 
knockout mice (strain unrelated to SKH-1 hairless mice) exposed to the DMBA/TPA skin 
tumorigenesis protocol compared to wild-type animals (Tiano, et al., 2002).  In contrast, 
transgenic mice that overexpress COX-2 developed significantly more tumors in 
comparison to their wild-type counterparts in UV-exposed animals (Fischer, et al., 
2007).  Topical application of the non-selective COX inhibitor indomethacin reduced 
chemically-induced skin tumor formation in mice (Muller-Decker and Furstenberger, 
2007).  In addition, topically or orally administered celecoxib or indomethacin also 
significantly reduced tumor formation and tumor size in animals exposed to the UV-light 
induced carcinogenesis protocol (Fischer, et al., 1999; Wilgus, et al., 2003).  These 
experimental findings show that the inhibition of COX-2 expression or activity blocks 
epidermal tumor growth.  Since we have shown that apigenin inhibits COX-2 expression 
its chemopreventative activity may be mediated by inhibition of COX-2.    
To definitively determine whether apigenin inhibits tumor formation by blocking 
COX-2, additional studies utilizing COX-2 knockout animals would be needed.  SKH-1 
homozygous COX-2 knockout mice (COX-2 -/-) could not be included in our study 
because these animals die shortly after birth due to an inability to close the ductus 
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arteriosus and due to various renal pathologies (Morham, et al., 1995; Loftin, et al., 
2001; Rundhaug, et al., 2007a).  As such, we planned to use SKH-1 heterozygous 
COX-2 knockout mice (COX-2 +/-) in our tumorigenesis study.  Our acute TPA exposure 
experiments showed that COX-2 +/- mice displayed levels of COX-2 expression that 
were similar to COX-2 +/+ mice (Figure 10).  We believe that the recessive allele of the 
COX-2 gene was knocked down rather than the dominant allele and as a result, the 
COX-2 gene was expressed at wild-type levels.  For this reason we omitted the 
heterozygous COX-2 animals from our tumorigenesis study.  
As an alternative approach to understand the role of COX-2 in the antitumor 
activity of apigenin, the expression of COX-2 was measured in tumors and in the 
surrounding epidermis.  Although the surrounding epidermis is non-tumor tissue it is 
abnormal because the animals in each experimental group were initiated with DMBA 
and chronically exposed to TPA.  Thus, the surrounding epidermis actually represents 
initiated skin.  We compared the expression of COX-2 in the surrounding epidermis of 
animals treated with DMBA/TPA or apigenin + DMBA/TPA and found that apigenin 
significantly decreased COX-2 expression.  Interestingly, another report showed that in 
DMBA-initiated mouse skin, the overexpression of COX-2 was sufficient to induce tumor 
formation (Muller-Decker, et al., 2002).  As such, apigenin’s ability to suppress COX-2 
expression in DMBA-initiated surrounding epidermis is likely a major event that is 
responsible for its chemopreventative activity.  
Various studies have also shown that EP1 receptor expression is critical for skin 
tumor development.  Results from our tumorigenesis study revealed that apigenin 
effectively blocked the DMBA/TPA-induced increase in EP1 receptor expression in the 
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surrounding epidermis.  We also observed that EP1 receptors were overexpressed in 
the tumorigenic keratinocyte cell line JWF-2 and not expressed in the non-tumorigenic 
cell line, HaCaT (Figure 13).  This expression pattern suggests that similar to COX-2, 
down regulation of EP1 is critical for antitumor activity of apigenin.  Accumulating 
evidence from many studies support this idea.  For instance, Watanabe et al. revealed 
that azoxymethane-induced aberrant crypt foci development in the colon was 
significantly inhibited in EP1 knockout versus wild-type mice or in wild-type mice treated 
with the EP1 antagonist, ONO-8711 (Watanabe, et al., 1999).  Additionally, topical 
application of an alternative selective EP1 antagonist, ONO-8713, reduced UVB-
induced skin tumor multiplicity (Tober, et al., 2006).  In contrast, overexpression of the 
EP1 receptor in the DMBA/anthralin (non-PKC activating tumor promoter) skin tumor 
model enhanced tumor development compared to DMBA/TPA treated animals, 
indicating that the tumor promoting activity of the EP1 receptor may be stimulus 
dependent (Surh, et al., 2011).   
The EP2 or EP4 receptors also promote tumor development.  For example, both 
DMBA/TPA- and UVB-induced carcinogenesis was blocked in EP2 heterozygous 
knockout animals compared to wild-type mice (Sung, et al., 2005; Chun, et al., 2007).  
Fewer tumors developed in UVB-exposed EP2 homozygous knockout mice compared 
with wild-type animals however the tumors from the EP2 knockout animals displayed a 
more aggressive phenotype (Brouxhon, et al., 2007).  Results from our tumorigenesis 
study show that apigenin inhibits DMBA/TPA-induced tumor development and the 
expression of EP2 in the surrounding skin again suggesting that apigenin-mediated 
down regulation of COX-2/PGE2 signaling is important for its antineoplastic activity.  In 
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another report, EP4 receptor inhibition by genetic ablation or chemical inhibition 
suppressed aberrant crypt formation induced by azoxymethane or spontaneous polyp 
development in Min mice (Mutoh, et al., 2002).  In contrast, the EP3 receptor does not 
appear to regulate carcinogenesis (Sung, et al., 2005).  In our investigation of the acute 
effect of apigenin on EP receptor expression, positive staining for EP3 and EP4 was not 
observed in our immunohistochemical data possibly due to the lack of epitope 
recognition by the antibody in intact tissue.  Therefore, the expression of EP3 and EP4 
was not examined in our tumor study.  These combined results suggest that the 
suppression of EP1 receptor expression mediated by apigenin is a likely mechanism by 
which DMBA/TPA-induced carcinogenesis is prevented.  
When analyzing COX-2/PGE2 signaling in epithelial tumors; COX-2, PGE2, EP1, 
and EP2 receptor expression were all elevated in DMBA/TPA treated animals.  Apigenin 
at both concentrations did not reduce COX-2 signaling in the tumors.  The expression of 
COX-2 is regulated by various signaling proteins including protein kinase B (PKB/Akt), 
upstream stimulatory factors (USF1/USF2), and the T-cell-restricted intracellular antigen 
1-related protein (TIAR) (Van Dross, et al., 2005; Tong, et al., 2007; Van Dross, et al., 
2007).  Akt is a serine/threonine kinase that functions downstream of 
phosphatidylinositol 3-kinase (PI3K) and induces COX-2 expression by activating 
transcription factors such as nuclear transcription factor kappa B (NF-kB) (Van Dross, et 
al., 2005; St-Germain, et al., 2004).  The transcription factors USF1 and USF2 increase 
UVB-light induced COX-2 expression in cultured keratinocytes (Van Dross, et al., 2007).   
Also, post-transcriptional regulation of COX-2 expression occurs through binding of 
TIAR to AU-rich elements (ARE) of the 3’-untranslated region of COX-2 mRNA 
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regulating its stability (Cok and Morrison, 2001; Tong, et al., 2007).  Our previous work 
shows that apigenin inhibits the synthesis of COX-2 by blocking these signaling 
pathways.  Since other signaling pathways also regulate COX-2 expression it is 
possible that COX-2/PGE2 signaling in AP5- and AP20 + DMBA/TPA animals was not 
decreased in the tumors due to the upregulation of alternative signaling pathways.  
Upregulation of alternative signaling pathways is a common mechanism of resistance 
for a number of chemotherapeutic agents.  For example, gefitinib and erlotinib are 
epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors used to treat non-
small cell lung cancer.  These tumors can become resistant through activation of c-
MET, a receptor tyrosine kinase, which can bypass EGFR and activate signaling 
molecules down-stream of EGFR (Garofalo, et al., 2012). 
Several reports show that upregulation of COX-2/PGE2 signaling promotes tumor 
development due to its ability to suppress terminal differentiation, promote proliferation, 
and/or block apoptotic signaling (Fischer, et al., 1989; Yuspa, et al., 1990; Sarasin, 
1999).  Under normal physiological conditions, terminal differentiation occurs in 
keratinocytes that lose their ability to self-renew after transition to the squamous 
epidermal layer.  Tumor cells are unable to terminally differentiate in order to promote 
cell survival.  COX-1 or COX-2 deficiency inhibits mouse skin tumor formation by 
inducing pre-mature terminal differentiation of keratinocytes after DMBA/TPA exposure 
(Tiano, et al., 2002; Lao, et al., 2012).  Another study showed that topical application of 
celecoxib induced premature terminal differentiation in mouse epidermis after acute 
TPA exposure (Akunda, et al., 2004).  Apigenin increases the number of K1 and K10 
positive keratinocytes in the basal layer of the surrounding epidermis.  These findings 
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imply that apigenin-mediated inhibition of COX-2 expression, PGE2 production, and EP 
receptor expression is likely responsible for the induction of premature terminal 
differentiation in our study.   
Cancer is a disease characterized by uncontrolled cell proliferation and 
numerous signaling molecules regulate this process.  COX-2 overexpression increases 
cell proliferation and epidermal hyperplasia in various in vivo and in vitro models 
through increased production of PGE2.  For example, addition of endogenous PGE2 to 
subconfluent cultured breast cells and keratinocytes resulted in an increased rate of 
proliferation (Pentland and Needleman, 1986; Konger, et al., 1998).  Tiano et al 
determined that papillomas from COX-2 knockout animals subjected to chemical 
carcinogenesis contained reduced levels of PGE2 as well as decreased BrdU-labeled 
proliferating keratinocytes compared to wild-type mice (Tiano, et al., 2002).  
Furthermore, recent studies have shown that EP1 and EP2 receptor activation induces 
cellular proliferation.  In EP1-/- mice a decrease in cell proliferation was observed in 
azoxymethane-induced colon tumors versus EP1+/+ animals (Kawamori, et al., 2005).  
Similar results were also observed in EP2 -/- mice exposed to TPA which displayed 
reduced keratinocyte proliferation in the epidermis compared to EP2 wild-type mice 
(Sung, et al., 2005).  Therefore, it is not surprising that fewer proliferating keratinocytes 
were observed in the epidermis of animals from the AP5 + DMBA/TPA and AP20 + 
DMBA/TPA treatment groups compared to animals treated with DMBA/TPA alone.  
Since we also determined that apigenin caused premature terminal differentiation, the 
blockade in cell proliferation may have triggered unscheduled entry into the terminal 
differentiation program.  Alternatively, premature activation of terminal differentiation 
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may have caused the block in cell proliferation.  This differentiation-proliferation switch 
has been described previously and could explain the mechanism of apigenin-mediated 
prevention of tumor development (Liu, et al., 2008; Zhu, et al., 2009). 
Several published reports and our previous data show that apigenin is a potent 
inducer of cellular apoptosis (Chen, et al., 1996; Van Dross, et al., 2005; Vargo, et al., 
2006; Balasubramanian and Eckert, 2007; Abu-Yousif, et al., 2008; Choi and Kim, 
2009).  Apoptosis is also known to be a functional consequence of the suppression of 
COX-2/PGE2 signaling (Arico, et al., 2002; Wu, et al., 2004; Akunda, et al., 2007).  We 
attempted to evaluate the induction of apoptosis in the surrounding epidermis and in 
tumors of DMBA/TPA-, AP5 + DMBA/TPA- and AP20 + DMBA/TPA-treated mice and 
observed a strong signal for activated caspase-3 in all of the analyzed samples.  Since 
differences in signal intensity among the treatment groups and within the individual 
epidermal layers were expected, these results suggest a lack of specificity in antibody 
target recognition.  In our studies, the induction of apoptosis was measured using an 
antibody directed against activated caspase-3.  The antibody recognizes a 
conformational epitope that is exposed in the activated protein or in the inactive protein 
that is denatured.  Therefore, it is critical that proteins in the tissue sections maintain the 
appropriate three-dimensional structure.  As such, only frozen tissue sections, but not 
paraffin embedded samples (which must be heated) are appropriate for this antibody.  
Because the staining in each of the samples was heavy and did not contain distinct 
patterns, we suspect that the proteins in our frozen sections may have become 
denatured at some stage during IHC tissue processing.  Our attempts to measure 
apoptosis with TUNEL assays in intact skin were also unsuccessful due to an 
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unacceptable level of background signal using a fluorescence approach.  The scarcity 
of studies that measure apoptosis in intact skin lead us to believe that the currently 
available techniques are not optimal for detection of apoptosis in the skin.   
Overall, results from specific aim 1 demonstrate that apigenin inhibits the acute 
TPA-mediated increase in COX-2 expression and activity in mouse epidermis dermis.  
Also, apigenin inhibits TPA-mediated induction in PGE2 production and EP1 receptor 
expression in SKH-1 mice.   Specific aim 2 shows that apigenin prevents DMBA/TPA-
mediated skin tumor formation and also prevents COX-2 expression, PGE2 production, 
EP1, and EP2 receptor expression in the surrounding epidermis of DMBA/TPA treated 
SKH-1 mice.  In addition, apigenin appears to prevent tumor development by promoting 
terminal differentiation and inhibiting cell proliferation in basal keratinocytes.  Because 
numerous studies have shown that the suppression of COX-2 expression/activity blocks 
tumor development, the reduction in COX-2/PGE2 signaling that we observed suggests 
that apigenin may prevent tumor development by inhibiting COX-2 expression, PGE2 
production, and EP receptor expression.  Thus, apigenin could provide additional 
treatment options for NMSC.  
In order to overcome the pitfalls of this study, future experiments will be required.  
In our tumorigenesis study, a vehicle control group was not included, because it is well 
known that SKH-1 mice do not spontaneously develop tumors.  By not including a 
vehicle-only group, data and statistical analysis was limited to comparing only apigenin 
+ DMBA/TPA treated animals to DMBA/TPA-treated animals.  In this study we were 
unable to utilize COX-2 +/- SKH-1 mice to determine the role of COX-2 in apigenin-
mediated inhibition of DMBA/TPA-induced carcinogenesis.  Other groups have utilized 
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the COX-2 +/- and COX-2 -/F1 agouti mouse strain.  However, hairless mice are 
preferred in our research because hair removal can produce scarring and inflammation 
which may confound our results.  To overcome this problem, a different COX-2 
knockout hairless strain will need to be identified.  Lastly, to overcome the issues we 
experienced determining apigenin’s effect on apoptosis, it will be necessary to identify 
an appropriate probe to detect apoptosis in intact skin in order to assess whether the 
inhibition of tumor development might also be regulated by apigenin’s ability to induce 
apoptosis. 
Our future goal is to develop a topical preparation of apigenin for prevention of 
skin cancer.  Apigenin could be useful for preventing skin cancer in individuals at high 
risk for developing skin cancer including the elderly, kidney transplant recipients, and 
xeroderma pigmentosa (XP) patients.  For example, aging individuals with a single 
tumor are at increased risk (44% increase for BCC and 18% increase for SCC) of 
developing a second tumor within 3 years (Marcil and Stern, 2000).  Approximately 30% 
of kidney transplant patients develop skin cancer as a likely result of chronic 
immunosuppression (Carroll, et al., 2003; Euvrard, et al., 2003).  Finally, XP is a rare 
disorder characterized by inherited mutations in the XP family of DNA repair enzyme 
genes.  On average, XP patients develop skin cancer by age 8 and succumb to cancer 
by age 20.  Apigenin could provide additional treatment options for these individuals 
who are at increased risk of developing skin cancer. 
The use of apigenin in a topical preparation also provides the benefit of 
selectively inhibiting COX-2 expression in the epidermis.  This route of administration 
avoids potential adverse cardiovascular effects observed with systemic administration of 
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COX-2 inhibitors.  Collectively, the use of apigenin or apigenin derivatives in a topical 
cream may be an effective and safe strategy to prevent the formation of cancer. 
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